Retatrutide is an investigational “triple-G” agonist (GLP-1, GIP, and glucagon receptor) designed to treat obesity and type 2 diabetes. Phase 2 trials showed significant benefits, including an average body weight loss of up to 24% over 48 weeks, enhanced fat burning, improved blood sugar control, and potential muscle preservation.